A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma (RADIOSARP)

A Phase Ib Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma

A phase Ib study of Olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma.

Study Overview

• Status: Completed
• Conditions: Soft-tissue Sarcoma
• Intervention / Treatment: Drug: Olaparib; Radiation: Concomitant Radiotherapy

Detailed Description

This is a multicenter, prospective phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing four dose levels of Olaparib given with concomitant radiotherapy, followed by an expansion cohort.

• Study Type: Interventional
• Enrollment (Actual): 41
• Phase: Phase 1

Contacts and Locations

Study Locations

• France
  • Bordeaux, France, 33076
    • Institut Bergonie
  • Lyon, France, 69373
    • Centre Leon Berard
  • Montpellier, France, 34298
    • Institut du Cancer de Montpellier
  • Toulouse, France, 31052
    • Institut Claudius Regaud - IUCT

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Histology: patients with soft-tissue sarcoma histologically confirmed by central review (Pr Coindre team), except if the diagnosis was already confirmed by the RRePS Network,
2. Upper/Lower limb or trunk wall soft-tissue sarcoma,
3. Age ≥ 18 years,
4. Locally advanced or locally recurrent primitive tumor, outside any previously irradiated field. Patients presenting operable locally Advanced or lacally recurrent tumor can be included. Patients with metastases can be included.
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2,
6. Life expectancy ≥ 6 months,
7. At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements,

8. Adequate hematological, renal, metabolic and hepatic function:

   • Haemoglobin ≥ 9 g/dL and no blood transfusions in the 14 days prior to study entry
   • Absolute neutrophil count (ANc) ≥ 1.5 x 109/L
   • Platelets ≥ 100 x 109/L
   • Total bilirubin ≤ 1.5 x upper limit of normality (ULN),
   • Alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) ≤ 2.5 x ULN,
   • Serum creatinine ≤ 150 μmol/L or creatinine clearance ≥ 50 mL/min (according to local institution) in case of serum creatinine > 150 μmol/L,
   • TP, INR ≤ 1.5 x ULN

9. Women of childbearing potential must have a negative serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1. Female patients of child bearing potential and their partners, who are sexually active, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for at least 1 month after last dose of study drug. Males patients, who are sexually active, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for at least 3 month after last dose of study drug. Acceptable birth control methods are described in appendix 10.

   Subjects of non-childbearing potential are those who have:

   • Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments,
   • LH and FSH levels in the post menopausal range for women under 50,
   • radiation-induced oophorectomy with last menses >1 year ago,
   • chemotherapy-induced menopause with >1 year interval since last menses,
   • or surgical sterilisation (bilateral oophorectomy or hysterectomy).
10. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up,
11. Voluntary signed and dated written informed consent prior to any specific procedure,
12. Patients with a social security in compliance with the Law.

Exclusion Criteria:

1. Any previous treatment with a PARP inhibitor, including Olaparib,
2. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication,
3. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy,
4. Patients with known active hepatic disease (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids,
5. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining informed consent,
6. Patients with uncontrolled seizures,
7. Men or women of childbearing potential who are not using an effective method of contraception as previously describes; women who are pregnant or breast feeding,
8. No prior or concurrent malignant disease diagnosed or treated in the last 2 years, except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,
9. Patients receiving any systemic chemotherapy within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used),
10. Concomitant use of known CYP3A4 inhibitors such as ketokonazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir,
11. Resting ECG with QTc > 470msec on 2 or more time points within a 24 hour period or family history of long QT syndrome,
12. Blood transfusions within 14 days prior to study start,
13. Patients with myelodysplastic syndrome/acute myeloid leukaemia,
14. Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery,
15. Participation to a study involving a medical or therapeutic intervention in the last 30 days,
16. Patient unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons,
17. Previous enrollment in the present study,
18. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
19. Patients who not have recovered from any effects of any major surgery
20. Individuals deprived of liberty or placed Under legal guardianship
21. Patients who have tumor in contact with, invading or encasing for more than 50% any major blood vessels

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Olaparib in association with concomitant radiotherapy; Olaparib will be administered per os bi-daily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression. Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.

Drug: Olaparib; Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.; Radiation: Concomitant Radiotherapy; Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)	We reported in the following the number of Participants who experienced DLT. A DLT is defined as an adverse event (AE) or laboratory abnormality that fulfills all the criteria below: 1/ Occurs during the period of observation of DLTs defined as the period between the first day of treatment administration and up to 6 weeks after the end of radiotherapy. 2/ Is considered to be at least possibly related to the treatment strategy (radiotherapy or Olaparib).3/ Is unrelated to disease, disease progression, inter-current illness, or concomitant medications. 4/ Meets some criteria (see protocole), graded according to NCI CTCAEv4.0	Until to six weeks after end of radiotherapy
Maximum Tolerated Dose (MTD) of Olaparib in Association With Radiotherapy	MTD was determined by testing increasing doses up 150mg twice a day on dose escalation cohorts 1 to 4 with 3 to 11 participants each. MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in > 33% of participants. DLTs were defined as any grade 3 or 4 adverse event according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0) that could be related to treatment (reported in the following primary outcome measure).	Up to 6 weeks after end of radiotherapy for each dosing cohort

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Non-progression at 6 Months as Per RECIST 1.1	6-month non progression rate is defined as the proportion of complete (CR) or partial response (PR) at 6 months confirmed ≥ 4 weeks after initial documentation, or stable disease (SD) more than 24 weeks (RECIST v1.1, as determined by investigator review of tumor assessments).	up to 6-month after treatment onset
Percentage of Participants With Objective Responses at 6 Months as Per RECIST 1.1	6-month objective response, defined as CR or PR at 6 months confirmed ≥ 4 weeks after initial documentation, as determined by investigator review of tumor assessments using RECIST v1.1	up to 6-month after treatment onset
Best Response Under Treatment as Per RECIST 1.1	Best response under treatment is defined as the best response (CR, PR, SD) as per RECIST 1.1 recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation as per RECIST v1.1 criteria. It is determined once all the data for the patient is known.	End of treatment, approximately 13.5 weeks atfer treatment onset
Progression-free Survival (PFS) as Per RECIST 1.1	PFS is defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause), whichever occurs first.	1 year after treatment onset
Overall Survival (OS)	OS is defined as the time from study treatment initiation to death (of any cause).	1 year after treatment onset
Musculoskeletal Tumor Society (MSTS) Functional Score	The Musculoskeletal Tumor Society (MSTS) score assesses functional outcomes before (week 2) and after (week 10) treatment with olaparib in combination with radiotherapy. It consists of six items (pain, function, emotional acceptance, and either support/walking/gait for lower limbs or positioning/dexterity/strength for upper limbs). Each item is rated 0-5, summed to a total score ranging from 0 (worst outcome) to 30 (best outcome). Higher scores represent better functional outcomes.	Two weeks after treatment onset

Collaborators and Investigators

• Sponsor: Institut Bergonié
• Collaborators: National Cancer Institute, France

Publications and helpful links

General Publications

• Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28439. doi: 10.1002/pbc.28439. Epub 2020 Aug 22.
• Sargos P, Sunyach MP, Ducassou A, Llacer C, Dinart D, Michot A, Valentin T, Firmin N, Blay JY, Gillon P, Bellera C, Italiano A. Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study. Ann Oncol. 2025 May;36(5):592-600. doi: 10.1016/j.annonc.2025.01.016. Epub 2025 Jan 31.

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2016
• Primary Completion (Actual): October 1, 2021
• Study Completion (Actual): May 1, 2022

Study Registration Dates

• First Submitted: May 2, 2016
• First Submitted That Met QC Criteria: May 26, 2016
• First Posted (Estimated): June 1, 2016

Study Record Updates

• Last Update Posted (Actual): February 25, 2026
• Last Update Submitted That Met QC Criteria: February 6, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Advanced soft-tissue sarcoma; Unresectable Soft-tissue Sarcoma
• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Connective and Soft Tissue; Sarcoma; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Poly(ADP-ribose) Polymerase Inhibitors; olaparib
• Other Study ID Numbers: IB 2015-05; 2015-003722-13 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO